196 573

Cited 4 times in

A Multicenter Phase III Study to Evaluate the Efficacy and Safety of Hepabulin, a New Hepatitis B Immunoglobulin, in Liver Transplantation Recipients with Hepatitis B

DC Field Value Language
dc.contributor.authorChoi, HJ-
dc.contributor.authorKim, DG-
dc.contributor.authorKim, SI-
dc.contributor.authorWang, HJ-
dc.contributor.authorJoh, JW-
dc.contributor.authorSuh, KS-
dc.contributor.authorKim, SH-
dc.date.accessioned2018-08-29T06:21:27Z-
dc.date.available2018-08-29T06:21:27Z-
dc.date.issued2017-
dc.identifier.issn1425-9524-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/16201-
dc.description.abstractBACKGROUND: This study was performed to evaluate the effects and stability of the new hepatitis B immunoglobulin (HBIG), Hepabulin, in patients undergoing liver transplantation for hepatitis B.
MATERIAL AND METHODS: A total of 87 patients undergoing liver transplantation for hepatitis B-related liver disease were enrolled in this multicenter, phase III, open-label, single-arm study. Seventy (80.5%) of the 87 enrolled patients completed the study during the 52-week study period. Hepabulin (10,000 units) was intravenously injected intraoperatively, daily for 1 week, weekly for 1 month, and then once per month. Hepabulin was used as monotherapy without antiviral agents. Hepatitis B recurrence was defined as conversion from negativity for surface antigen after HBIG administration to positivity.
RESULTS: There were no cases of hepatitis B recurrence during the 52-week observation period. A total of 876 adverse events (AEs) that occurred during the study period were observed in 83 (95.4%) of 87 patients, and serious AEs were seen in 119 cases in 44 (50.6%) of the 87 patients. None of the AEs showed a relationship with this drug. Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) rapidly disappeared within 1 week after HBIG administration, but hepatitis B virus (HBV) DNA persisted for up to 8 weeks after surgery, which was related to HBV viral load. Hepatitis B surface antibody (HBsAb) was correlated with HBIG (Hepabulin) dose.
CONCLUSIONS: The new HBIG, Hepabulin, was shown to be safe and effective in preventing the recurrence of HBV after liver transplantation.
-
dc.language.isoen-
dc.subject.MESHHepatitis B Antibodies-
dc.subject.MESHHepatitis B virus-
dc.subject.MESHLiver Transplantation-
dc.titleA Multicenter Phase III Study to Evaluate the Efficacy and Safety of Hepabulin, a New Hepatitis B Immunoglobulin, in Liver Transplantation Recipients with Hepatitis B-
dc.typeArticle-
dc.contributor.affiliatedAuthor왕, 희정-
dc.type.localJournal Papers-
dc.identifier.doi10.12659/aot.905898-
dc.citation.titleAnnals of transplantation-
dc.citation.volume22-
dc.citation.date2017-
dc.citation.startPage740-
dc.citation.endPage748-
dc.identifier.bibliographicCitationAnnals of transplantation, 22. : 740-748, 2017-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn2329-0358-
dc.relation.journalidJ014259524-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Files in This Item:
10.12659_aot.905898.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse